Date | Title | Description |
25.05.2023 | Strong long-term results with CERAMENT®G for severe open fra... | Published: 2023-05-25
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone... |
23.05.2023 | Spruce Biosciences Honored at CARES Foundation 15th Annual E... | Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, accepted the Corporate Partner Award
SOUT... |
23.05.2023 | Vicore obtains significant new patent protection for C21 in ... | Stockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of... |
19.05.2023 | Vicore reports new 36-week data from the AIR trial demonstra... | Stockholm, May 19, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a n... |
17.05.2023 | Vicore to host webcast with updated AIR trial results after ... | Stockholm, May 17, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”), unlocking the potential of... |
16.05.2023 | Aprea Therapeutics Reports First Quarter 2023 Financial Resu... | DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, o... |
15.05.2023 | Spruce Biosciences Reports First Quarter 2023 Financial Resu... | CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CA... |
12.05.2023 | Oncopeptides presents new data at the European Haematology A... | May 11, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research... |
12.05.2023 | Carisma Therapeutics Reports First Quarter 2023 Financial Re... | Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients w... |
12.05.2023 | Fusion Pharmaceuticals Announces First Quarter 2023 Financia... | FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update
Preliminary P... |
12.05.2023 | UCB and Ariceum Therapeutics sign a Strategic Research Colla... | Berlin, Germany, and Brussels, Belgium, 11 May 2023 – Ariceum Therapeutics (Ariceum), a private biot... |
11.05.2023 | 100% limb salvage rate in complex diabetic foot cases with C... | Published: 2023-05-10
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone... |
11.05.2023 | HelloBetter received FDA Breakthrough Device Designation for... | Berlin, Germany, April 2023 – HelloBetter, one of the world’s leading providers in developing and co... |
04.05.2023 | Oncopeptides publishes Q1 report 2023 | May 4, 2023
Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused ... |
04.05.2023 | Interim report January-March 2023 | 2023-05-04| REGULATORY
Stockholm, May 4, 2023 – Vicore Pharma Holding AB (publ), unlocking the pote... |
03.05.2023 | Fusion Pharmaceuticals Announces Opening Of Radiopharmaceuti... | HAMILTON, ON, May 2, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stag... |
03.05.2023 | Pulmonx Reports First Quarter 2023 Financial Results | REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” ... |
03.05.2023 | Vicore initiates clinical proof-of-concept study of endothel... | Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of... |
03.05.2023 | Oncopeptides issues warrants to utilize the first loan tranc... | May 3, 2023 Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused o... |
02.05.2023 | Invitation to presentation of the Q1 report 2023 | May 2, 2023
Oncopeptides AB (publ) a biotech company focused on research, development, and commerci... |
27.04.2023 | BONESUPPORT HOLDING AB (publ) – Publishes Q1 2023 interim re... | Published: 2023-04-27
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the ma... |
25.04.2023 | Oncopeptides publishes the 2022 Annual Report | April 25, 2023
Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focus... |
21.04.2023 | Oncopeptides presents new scientific data at European Myelom... | April 20, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on resea... |
21.04.2023 | Fusion Pharmaceuticals Announces Presentation Of Preclinical... | FPI-2059 induces tumor growth inhibition in colorectal tumor model
TEM-1 and EGFRvIII demonstrate p... |
18.04.2023 | Ariceum Therapeutics Announces Extension of Series A Financi... | Berlin, Germany, 18 April 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developin... |
17.04.2023 | Carisma Therapeutics to Present at The American Association ... | PHILADELPHIA, PA – April 14, 2023 – Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage bioph... |
14.04.2023 | Adcendo ApS to Present Data on the Expression of the Novel A... | Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the deve... |
14.04.2023 | Fusion Pharmaceuticals Announces IND Clearance For FPI-2068,... | FPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tum... |
05.04.2023 | Vicore Pharma publishes the Annual Report for 2022 | Stockholm, April 5, 2023 –Vicore Pharma Holding AB (publ) (“Vicore” or “company”) unlocking the pote... |
05.04.2023 | Carisma Therapeutics Reports Fiscal 2022 Financial Results a... | Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol “CARM”
Cash positi... |
04.04.2023 | Adcendo ApS Announces Extension of Series A financing to 82M... | Copenhagen, Denmark, April 4th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the dev... |
01.04.2023 | Vicore to announce AIR trial update at the ATS congress on M... | Stockholm, March 31, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a... |
01.04.2023 | Doctrin receives ISO/IEC 27001 certification | 2023-03-31
Doctrin is proud to announce that the company has received its ISO/IEC 27001:2013 certif... |
01.04.2023 | Aprea Therapeutics Reports Fourth Quarter and Full Year 2022... | DOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,... |
30.03.2023 | Vicore receives Innovation Passport designation by the UK re... | Stockholm, March 29, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a... |
28.03.2023 | Oncopeptides receives a research grant from Sweden´s Innovat... | March 28, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on resea... |
22.03.2023 | Fusion Pharmaceuticals Announces First Patient Dosed In Phas... | HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a... |
17.03.2023 | Spruce Biosciences Reports Full Year 2022 Financial Results ... | CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment
Private Placement Financing of $53.6 mil... |
16.03.2023 | Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financi... | Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a sm... |
15.03.2023 | Targovax ASA: circRNA poster to be presented at the AACR Ann... | Oslo, Norway, 15 March 2023 – Targovax ASA (OSE: TRVX) today announces that an abstract describing i... |
14.03.2023 | Targovax: First patient dosed with TG01 in the USA | Oslo, Norway, 14 March 2023 – Targovax ASA (OSE: TRVX), today announces that the first patient has b... |
10.03.2023 | Oncopeptides CSO released from custody | March 10, 2023
Regulatory
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focu... |
08.03.2023 | Oncopeptides CSO investigated for violation of the Market Ab... | March 8, 2023
Regulatory
Oncopeptides AB (publ), has been informed by the Swedish Economic Crime A... |
08.03.2023 | Carisma Therapeutics Closes Merger with Sesen Bio | Shares of Carisma to commence trading on Nasdaq under new ticker symbol “CARM” on March 8, 2023
Res... |
08.03.2023 | Targovax to prioritize resources on unlocking the potential ... | Oslo, Norway, 7 March 2023 Targovax ASA (OSE: TRVX) today announces that it will focus existing fina... |
03.03.2023 | Hemab Therapeutics’ Statement Announcing the Planned Departu... | COPENHAGEN, Demark and BOSTON, March 1, 2023
Hemab Therapeutics, a clinical-stage biotechnology com... |
03.03.2023 | Sesen Bio Stockholders Approve Merger with Carisma Therapeut... | Declares Special Dividend in the Aggregate of $75 Million
Approximately 88% Voted in Favor of the M... |
02.03.2023 | Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bi... | DOYLESTOWN, Pa., March 01, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,... |
28.02.2023 | Aprea Therapeutics Announces Closing of $5.5 Million Underwr... | DOYLESTOWN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, ... |
28.02.2023 | Year-end report 2022 | Stockholm, February 28, 2023 – Vicore Pharma Holding AB (publ) publishes the year-end report for 202... |
24.02.2023 | Pulmonx Reports Fourth Quarter and Full Year 2022 Financial ... | REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”... |
24.02.2023 | Aprea Therapeutics Announces Pricing of $5.5 Million Underwr... | DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, ... |
22.02.2023 | HealthCap Portfolio Company Hemab Therapeutics raises $135M ... | HealthCap VIII portfolio company Hemab Therapeutics today announced the closing of an oversubscribed... |
16.02.2023 | Oncopeptides publishes year-end report 2022 | February 16, 2023
Regulatory
Oncopeptides AB (publ), a biotech company focused on research, develo... |
16.02.2023 | BONESUPPORT HOLDING AB (publ) – publishes year-end report 20... | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuri... |
16.02.2023 | Targovax ASA: Fourth quarter 2022 results | Oslo, Norway, 16 February 2023 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company de... |
16.02.2023 | Targovax announces financing of up to NOK 300m over three ye... | Oslo, Norway, 16 February 2023 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company ... |
16.02.2023 | Aprea Therapeutics Announces Phase II SBIR Award from the Na... | DOYLESTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biophar... |
16.02.2023 | Sesen Bio and Carisma Therapeutics Announce Increased Specia... | Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Continge... |
15.02.2023 | Fusion Pharmaceuticals To Acquire Phase 2 Program For 225Ac-... | Acquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of in... |
14.02.2023 | Aprea Therapeutics Announces One-for-Twenty Reverse Stock Sp... | DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Comp... |
10.02.2023 | Invitation to presentation of the year-end report 2022 | Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development ... |
10.02.2023 | Targovax ASA: Invitation to Targovax’s fourth quarter 2022 p... | Oslo, Norway, 8 February 2023 – Targovax ASA (OSE: TRVX) will announce its fourth quarter 2022 resul... |
10.02.2023 | Pulmonx to Report Fourth Quarter and Full Year 2022 Financia... | REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”... |
10.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement... | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 9, 2023– Spruce Biosciences, Inc. (Nasdaq: SPRB), a... |
09.02.2023 | Carisma Therapeutics Appoints Moderna CSO of External Resear... | PHILADELPHIA, Feb. 7, 2023 /PRNewswire/ — Carisma Therapeutics Inc., a clinical stage biopharmaceuti... |
02.02.2023 | Carisma Therapeutics Appoints Leading Solid Tumor Immunother... | Expansion of Scientific Advisory Board provides additional expertise in development capabilities
PH... |
02.02.2023 | Ariceum Therapeutics Appoints Radioligand Expert, Germo Geri... | Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company develop... |
31.01.2023 | Aprea Therapeutics Appoints John Hamill as Chief Financial O... | DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biophar... |
24.01.2023 | Priothera announces first patients enrolled in pivotal MO-TR... | Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneeri... |
19.01.2023 | HelloBetter Sleep: First online therapy programme for organi... | Berlin, 20.12.2022 – HelloBetter Sleep has secured approval as HelloBetter’s sixth DiGA (prescriptio... |
11.01.2023 | Oncopeptides appoints Holger Lembrer as Chief Financial Offi... | STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company f... |
11.01.2023 | Aprea Therapeutics Announces Dosing of First Patient in Phas... | DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biophar... |
11.01.2023 | Hemab Therapeutics Announces First Patient Dosed in Phase 1/... | Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorde... |
09.01.2023 | Spruce Biosciences Provides Clinical Program Updates and Out... | Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated ... |
07.01.2023 | Fusion Pharmaceuticals And BWXT Medical Announce Actinium-22... | – Agreement augments Fusion’s existing isotope supply as pipeline of clinical stage actinium-based r... |
07.01.2023 | Spruce Biosciences and Kaken Pharmaceutical Announce Strateg... | Partnership aims to accelerate global development and commercialization plans for tildacerfont to ad... |
05.01.2023 | Adcendo ApS Announces License Agreement with Duality Biologi... | Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the dev... |
05.01.2023 | Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg a... | STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company fo... |
03.01.2023 | Sesen Bio and Carisma Therapeutics Announce Substantial Incr... | Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend i... |
22.12.2022 | Targovax announces that the TG01 study in multiple myeloma a... | Oslo, Norway, 22 December 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company ... |
15.12.2022 | American Lung Association Campaign Shines Spotlight on Endob... | Pulmonx Highlights 2022 Partnership with Lung Association
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Dec.... |
15.12.2022 | Targovax announces clinical trial collaboration with Agenus ... | Oslo, Norway, 15 December 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company ... |
15.12.2022 | Marston Forest Healthcare live with Doctrin – the next gener... | Press release – 15 December 2022
Marston Forest Healthcare, a 10,000 patient GP practice in Berkshi... |
13.12.2022 | Oncopeptides presents new scientific data at the Annual Amer... |
STOCKHOLM — December 12, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company... |
09.12.2022 | Vicore has carried out a directed share issue of 10,000,000 ... | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO... |
07.12.2022 | Oncopeptides provides update on Pepaxto US marketing authori... | STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech co... |
05.12.2022 | Vicore announces first patient enrolled in COMPANION; a digi... | Stockholm, December 5, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a pioneer in the developme... |
01.12.2022 | Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronch... | Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Dis... |
26.11.2022 | Oncopeptides enters into a renewed loan facility agreement o... | STOCKHOLM — November 25, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company f... |
16.11.2022 | Priothera – Positive mocravimod Phase 1b clinical data publi... | Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patient... |
11.11.2022 | Oncopeptides’ Pepaxti has been granted marketing authorizati... | STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company f... |
11.11.2022 | Spruce Biosciences Reports Third Quarter 2022 Financial Resu... | CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment
Appointment... |
10.11.2022 | Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from ... | Oslo, Norway, 10 November 2022 – Targovax ASA (OSE: TRVX) and Hubro Therapeutics AS (Hubro) today an... |
10.11.2022 | Aprea Therapeutics Reports Third Quarter 2022 Financial Resu... | BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutica... |
09.11.2022 | Oncopeptides publishes Q3 report 2022 | STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company fo... |
09.11.2022 | Fusion Pharmaceuticals Announces Third Quarter 2022 Financia... | FPI-1434 Phase 1 data on track to be reported in first half of 2023
Phase 1/2 Study of FPI-1966 ope... |
09.11.2022 | Oncopeptides announces the market potential for Pepaxti in E... | STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company fo... |
04.11.2022 | Vicore announces new data from the IPF AIR trial further str... | Stockholm, November 3, 2022 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”), a pioneer... |
04.11.2022 | Pulmonx Reports Third Quarter 2022 Financial Results | REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”... |